Risk Grading SystemNCT07412158
The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
An observational study of Risk Grading System and Pheochromocytoma and Paraganglioma (PPGL), run by Peking University First Hospital at 1 site in China.
Trial summary
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment
- What is being tested?
- observational diagnostic model development
- How many people
- 600 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2017to 1 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who underwent surgical resection and were definitively diagnosed with pheochromocytoma or paraganglioma (PPGL) by postoperative pathology at Peking University First Hospital between January 1, 2017 and December 31, 2025 were included in this study.
Who may be able to join
- ① Patients who underwent curative surgical resection (including laparoscopic, robot-assisted, or open surgery) at our hospital within the study period;
- Postoperative pathological confirmation of PPGL;
- Availability of complete preoperative imaging data; ④ Availability of complete perioperative clinical data, including anesthesia records, surgical records, and postoperative hospitalization information; ⑤ Age ≥ 18 years.
Who cannot join
- ① Lack of key imaging data or poor image quality that could not meet evaluation requirements;
- Requirement for concurrent complex surgery for other diseases, making it difficult to independently assess perioperative indicators; ③ History of biopsy only, exploratory surgery, or presence of recurrence, bilateral, or multifocal lesions, preventing independent evaluation; ④ Primary tumors located in special sites (e.g., pelvic, bladder, spermatic cord, or other rare extra-adrenal locations), leading to incomparable surgical approaches and perioperative outcomes.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Urology, Peking University First Hospital, Beijing, 100034
Beijing
About this study
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
- Being tested
- observational diagnostic model development
- Medical subject headings
- Pheochromocytoma, Paraganglioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observational diagnostic model developmentOther
observational diagnostic model development
What is being measured
The primary outcome is the main question the study is designed to answer.
Operative Time
Measured: Intraoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start1 Jan 2017
- Primary completion1 Aug 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Risk Grading SystemStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 600 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07412158
- Sponsor's protocol ID
- PKU-PPGL-IMG-2025-001
- Status last verified
- Jan 2017
- First submitted
- 17 Dec 2025
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
- ClinicalTrials.gov ID
- NCT07412158
- Acronym / sponsor ID
- PKU-PPGL-IMG-2025-001
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 600 participants (actual)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 1 Jan 2017 (actual)
- Primary completion
- 1 Aug 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who underwent surgical resection and were definitively diagnosed with pheochromocytoma or paraganglioma (PPGL) by postoperative pathology at Peking University First Hospital between January 1, 2017 and December 31, 2025 were included in this study.
Key inclusion criteria (3 listed)
- ① Patients who underwent curative surgical resection (including laparoscopic, robot-assisted, or open surgery) at our hospital within the study period;
Key exclusion criteria (2 listed)
- ① Lack of key imaging data or poor image quality that could not meet evaluation requirements;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observational diagnostic model developmentobservational diagnostic model development | Other | – |
Primary outcome
Operative Time
Time frame: Intraoperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Individual participant dataSharing planned: Yes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Risk Grading System and Pheochromocytoma and Paraganglioma (PPGL), run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Operative Time (time frame: Intraoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.